A5021815069- Immune cells in cancer
- Cancer Immunotherapy and Biomarkers
- Inflammatory mediators and NSAID effects
- Immunotherapy and Immune Responses
- Cancer, Hypoxia, and Metabolism
- Immune Cell Function and Interaction
- Genomics, phytochemicals, and oxidative stress
- Heart Failure Treatment and Management
- Eicosanoids and Hypertension Pharmacology
- Mechanical Circulatory Support Devices
- Toxic Organic Pollutants Impact
- Nosocomial Infections in ICU
- Tryptophan and brain disorders
Boston University
2020-2025
University of Michigan
2025
While immunotherapy has shown some efficacy in lung adenocarcinoma (LUAD) patients, many respond only partially or not at all. One limitation improving outcomes is the lack of a complete understanding immune checkpoint regulation. Here, we investigated possible link between an environmental chemical receptor implicated cancer and regulation, AhR, known but counterintuitive mediator immunosuppression (interferon (IFN)-γ), regulation two checkpoints (PD-L1 IDO). AhR gene-edited LUAD cell...
Although immune checkpoint inhibitors show great promise, not all patients respond and many do achieve durable responses. Consequently, further investigations into potentially targetable molecules that regulate checkpoints are warranted. Previous studies in several cancers demonstrated interferons produced by tumor-infiltrating leukocytes immunosuppressive PD-L1, PD-L2 IDO1 through JAK/STAT signaling. Here, we investigated a novel role for an environmental chemical receptor, previously...
Abstract While immunotherapy has shown efficacy in lung adenocarcinoma (LUAD) patients, many respond only partially or not at all. One limitation improving outcomes is the lack of a complete understanding immune checkpoint regulation. Here, we investigated possible link between an environmental chemical receptor implicated cancer and regulation, ( aryl hydrocarbon receptor/AhR), known but counterintuitive mediator immunosuppression (IFNγ), regulation two checkpoints (PD-L1 IDO). AhR...
Abstract Non-small cell lung cancer (NSCLC) is the second most common and accounts for ~127,000 deaths/year in U.S. Its current ~30% five-year survival rate an improvement from a decade ago thanks part to introduction of immune checkpoint inhibitors including PD1- PD-L1-specific monoclonal antibodies. While PD-1/PD-L1-targeted immunotherapy effective many cases, not all patients respond complete remissions still only occur minority patients. Therefore, greater understanding regulation human...
Abstract Immunotherapy has shown dramatic results in treating cancer, but only a minority of patients benefit. Therefore, there is an unmet medical need to understand the regulation immune suppression tumors. We show that aryl hydrocarbon receptor (AhR) central player regulating checkpoints mouse model lung adenocarcinoma (LUAD). Within murine malignant cell, AhR regulates expression several genes important suppressive signaling, including PD-L1. find similar immune-related regulatory...
Abstract Immunotherapy has shown dramatic results in treating cancer but only a minority of patients, so there is unmet need to understand the regulation immune suppression tumors. We have that aryl hydrocarbon receptor (AhR) central player regulating checkpoints oral squamous cell carcinoma (OSCC) and may play similar role lung cancer. Orthotopic transplant mouse AhR-knockout (KO) OSCC (MOC1) cells led complete rejection tumor formation coupled with increased T activation draining lymph...